OCT 05, 2016 10:30 AM PDT

Immunotherapy of Cancer Using Genetically-Enhanced T Cells

Speaker
  • Assistant Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania, Associate Director, Toxicology Laboratory, University of Pennsylvania Perelman Scho
    Biography
      Dr. Milone received his M.D. and Ph.D. in experimental pathology in 1999 from Rutgers-New Jersey Medical School (formerly the University of Medicine and Dentistry of New Jersey). After an Internship in Internal Medicine at the Hospital of the University of Pennsylvania, he completed post-graduate medical training in Clinical Pathology, Transfusion Medicine and Laboratory Toxicology. Following clinical training, Dr. Milone pursued post-doctoral research training in cancer immunology and adoptive immunotherapy with Dr. Carl June at the University of Pennsylvania where he performed basic research to develop CTL019, a genetically modified T cell therapy for B-cell leukemia and lymphoma that has been licensed by Novartis and undergoing early phase clinical testing. He is currently an Assistant Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. At present, Dr. Milone's laboratory is focused on T cell biology and the development of new techniques for culturing and genetically modifying T lymphocytes for adoptive immunotherapy of cancer.

    Abstract

    The immune system possesses significant cytotoxic potential. Stimulating natural immunity through vaccination has shown promising effects in some cancers; however, a number of barriers limit the efficacy of the natural immune system including tolerance to self-antigens and immunodeficiency associated with cancer and associated chemotherapy.  Adoptive immunotherapy using T-cells that are genetically modified to express an artificial receptor that combines the antigen specificity of an antibody with the signal transduction machinery of the T-cell receptor in a single chimeric antigen receptor (CAR) hold significant promise for overcoming many of the barriers to anti-cancer immunity.  This talk will describe the clinical applications of CARs that target CD19, a molecule expressed by normal B-cells and cells in a range of B-cell malignancies including acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) as well as a CARs targeting BCMA for multiple myeloma and mesothelin for solid malignancies. Toxicity related to this cell therapy that includes a cytokine release syndrome and long term B-cell aplasia will also be discussed.
     


    Show Resources
    You May Also Like
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    OCT 29, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    MAY 08, 2020 10:00 AM PDT
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    SEP 03, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 03, 2020 9:00 AM PDT
    DATE: September 3, 2020 TIME: 09:00am PT, 12:00pm ET xxx Learning Objectives: xxx Webinars will be available for unlimited on-demand viewing after live event. LabRoots is approved as a provi...
    JUN 17, 2020 1:30 PM PDT
    C.E. CREDITS
    JUN 17, 2020 1:30 PM PDT
    Understanding the complex interplay between a pathogen and the host response is important to developing effective vaccines and therapeutics. The nCounter® Analysis System and GeoMx®...
    C.E. CREDITS
    This drug development program is designed to create a family of broad-spectrum, pan-coronaviral drugs that respectively inhibit multiple key enzymes required for viral replication. By target...
    Loading Comments...
    Show Resources
    Attendees
    • See more